QNCX · Insider Trading
Quince Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by QNCX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | David Lamond | Director | A | +2,700 deriv. | — |
| 2026-06-15 | Christopher J. Senner | Director | A | +2,700 deriv. | — |
| 2026-06-11 | Brigette Roberts | Chief Corp. Affairs Officer | A | +16,698,162 deriv. | — |
| 2026-01-23 | Charles S. Ryan | President | A | +200,000 deriv. | — |
| 2026-01-23 | Dirk Thye | CEO and CMO | A | +1,000,000 deriv. | — |
| 2026-01-23 | Brendan Hannah | CBO, COO & CCO | A | −365,000 deriv. | — |
| 2026-01-21 | Christopher J. Senner | Director | A | +21,810 deriv. | — |
| 2026-01-21 | June Bray | Director | A | +18,724 deriv. | — |
| 2026-01-21 | Margaret McLoughlin | Director | A | +19,547 deriv. | — |
| 2026-01-21 | David Lamond | Director | A | +29,423 deriv. | — |
| 2025-12-29 | Luca Benatti | Director | J | +8,918 | — |
| 2025-12-29 | Luca Benatti | Director | Sell | −50,000 | −$173.50K |
| 2025-12-12 | Dirk Thye | CEO and CMO | G | — | — |
| 2025-12-08 | Brendan Hannah | CBO, COO & CCO | M | +27,551 | +$25.01K |
| 2025-06-23 | Brendan Hannah | CBO, COO & CCO | A | +37,736 | +$45.28K |
| 2025-06-23 | Dirk Thye | CEO and CMO | A | +150,944 | +$181.13K |
| 2025-06-23 | Charles S. Ryan | President | A | +7,548 | +$9.06K |
| 2025-06-06 | David Lamond | Director | A | +27,000 deriv. | — |
| 2025-06-06 | Rajiv Patni | Director | A | +27,000 deriv. | — |
| 2025-06-06 | Luca Benatti | Director | A | +27,000 deriv. | — |
| 2025-06-06 | Christopher J. Senner | Director | A | +27,000 deriv. | — |
| 2025-06-06 | Una S Ryan | Director | A | +27,000 deriv. | — |
| 2025-06-06 | June Bray | Director | A | +27,000 deriv. | — |
| 2025-06-06 | Margaret McLoughlin | Director | A | +27,000 deriv. | — |
| 2025-02-11 | Dirk Thye | CEO AND CHIEF MEDICAL OFFICER | A | +1,200,000 deriv. | — |
| 2025-02-11 | Brendan Hannah | CBO, COO and CCO | A | +450,000 deriv. | — |
| 2025-02-11 | Charles S. Ryan | PRESIDENT | A | +300,000 deriv. | — |
| 2025-01-08 | June Bray | Director | A | +30,282 deriv. | — |
| 2025-01-08 | Margaret McLoughlin | Director | A | +31,613 deriv. | — |
| 2025-01-08 | Christopher J. Senner | Director | A | +35,274 deriv. | — |
| 2025-01-08 | David Lamond | Director | A | +47,587 deriv. | — |
| 2024-09-03 | Dirk Thye | CEO AND CHIEF MEDICAL OFFICER | Buy | +154,500 | +$107.38K |
| 2024-08-22 | Charles S. Ryan | PRESIDENT | Buy | +48,387 | +$31.45K |
| 2024-08-21 | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Buy | +38,924 | +$24.17K |
| 2024-06-07 | Christopher J. Senner | Director | A | +27,000 deriv. | — |
| 2024-06-07 | Una S Ryan | Director | A | +27,000 deriv. | — |
| 2024-06-07 | Luca Benatti | Director | A | +27,000 deriv. | — |
| 2024-06-07 | Rajiv Patni | Director | A | +13,500 deriv. | — |
| 2024-06-07 | David Lamond | Director | A | +27,000 deriv. | — |
| 2024-06-07 | June Bray | Director | A | +27,000 deriv. | — |
| 2024-06-07 | Margaret McLoughlin | Director | A | +27,000 deriv. | — |
| 2024-06-05 | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | M | +56,061 | +$30.83K |
| 2024-02-15 | Rajiv Patni | Director | A | +54,000 deriv. | — |
| 2024-02-02 | Charles S. Ryan | PRESIDENT | A | +145,000 deriv. | — |
| 2024-02-02 | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | A | +600,000 deriv. | — |
| 2024-02-02 | Dirk Thye | CEO AND CHIEF MEDICAL OFFICER | A | +1,500,000 deriv. | — |
| 2024-01-17 | Dirk Thye | CHIEF EXECUTIVE OFFICER | M | +240,530 | +$190.79K |
| 2023-12-14 | David Lamond | Director | Buy | +67,881 | +$69.23K |
| 2023-12-07 | David Lamond | Director | Buy | +57,369 | +$58.13K |
| 2023-12-01 | David Lamond | Director | Buy | +43,134 | +$40.55K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Lamond | Director | 23,136 | $734.11K |
| Dirk Thye | CEO and CMO | 4,974 | $157.83K |
| Brendan Hannah | CBO, COO & CCO | 1,683 | $53.40K |
| Charles S. Ryan | President | 650 | $20.62K |
| Luca Benatti | Director | 196 | $6.22K |
| Margaret McLoughlin | Director | 40 | $1.27K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QNCX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.